Market closed
Capricor/CAPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Ticker
CAPR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
102
Website
Capricor Metrics
BasicAdvanced
$765M
Market cap
-
P/E ratio
-$0.93
EPS
4.02
Beta
-
Dividend rate
Price and volume
Market cap
$765M
Beta
4.02
52-week high
$17.51
52-week low
$2.68
Average daily volume
4.5M
Financial strength
Current ratio
1.372
Quick ratio
1.334
Long term debt to equity
9.077
Total debt to equity
15.969
Management effectiveness
Return on assets (TTM)
-44.49%
Return on equity (TTM)
-392.69%
Valuation
Price to revenue (TTM)
23.866
Price to book
60.2
Price to tangible book (TTM)
60.2
Price to free cash flow (TTM)
-17.975
Growth
Revenue change (TTM)
187.15%
Earnings per share change (TTM)
-19.99%
3-year revenue growth (CAGR)
339.61%
3-year earnings per share growth (CAGR)
3.47%
What the Analysts think about Capricor
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Capricor Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Capricor Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Capricor News
AllArticlesVideos
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
GlobeNewsWire·2 days ago
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Benzinga·4 days ago
Capricor Therapeutics is up over 100%, Could Rise Even Higher
MarketBeat·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $765M as of October 06, 2024.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of October 06, 2024.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of October 06, 2024.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 4.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.